HomeRV7 • FRA
add
Halozyme Therapeutics, Inc.
Nakaraang pagsara
€48.48
Sakop ng araw
€48.72 - €49.01
Sakop ng taon
€30.78 - €49.01
Market cap
6.73B USD
Average na Volume
20.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Mar 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 195.88M | 20.81% |
Gastos sa pagpapatakbo | 52.90M | -4.16% |
Net na kita | 76.82M | 93.92% |
Net profit margin | 39.22 | 60.54% |
Kita sa bawat share | 0.79 | 68.09% |
EBITDA | 114.35M | 56.94% |
Aktuwal na % ng binabayarang buwis | 20.00% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Mar 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 463.45M | 68.16% |
Kabuuang asset | 1.84B | 8.36% |
Kabuuang sagutin | 1.66B | 1.84% |
Kabuuang equity | 177.81M | — |
Natitirang share | 127.27M | — |
Presyo para makapag-book | 34.63 | — |
Return on assets | 13.36% | — |
Return on capital | 14.36% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 76.82M | 93.92% |
Cash mula sa mga operasyon | 129.43M | 48.83% |
Cash mula sa pag-invest | -82.68M | -37.43% |
Cash mula sa financing | -489.00K | 99.70% |
Net change in cash | 46.26M | 133.57% |
Malayang cash flow | 110.72M | 89.09% |
Tungkol
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
Itinatag
1998
Headquarters
Website
Mga Empleyado
373
